查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球肾纤维化治疗市场研究与预测：按治疗剂、最终用户和地区分列的分析，2022-2029 年
市场调查报告书
商品编码
1151999

全球肾纤维化治疗市场研究与预测：按治疗剂、最终用户和地区分列的分析，2022-2029 年

Global Kidney Fibrosis Treatment Market Size study & Forecast, by Therapeutics, by End User and Regional Analysis, 2022-2029
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

肾纤维化是指细胞外基质 (ECM) 蛋白在肾臟间质中的过度产生和沈积。

这种 ECM 的过度产生和沈积会导致结构损伤和肾功能下降，从而导致终末期肾病 (ESRD)。肾纤维化的两个主要原因是糖尿病和高血压。传染性肾小球肾炎、肾血管炎、输尿管梗阻、遗传异常、自身免疫性疾病等也会引起肾纤维化。慢性肾脏病发病率的增加、肾纤维化治疗意识的提高以及主要市场参与者的战略举措是推动市场增长的关键因素。

根据疾病控制和预防中心的数据，到 2021 年，大约 3700 万美国人将患有慢性肾病，占所有美国成年人的 15% 以上。此外，国家肾臟基金会估计，美国七分之一以上的成年人被诊断患有慢性肾病。此外，大约 90% 的肾病患者并不知道自己的疾病。此外，政府当局越来越积极的举措以及与生活方式相关的疾病患病率上升也有望在预测期内为市场提供良好的增长前景。然而，与监管审批相关的复杂流程将阻碍整个 2022-2029 年预测期内的市场增长。

全球肾纤维化治疗市场研究考虑的主要区域包括亚太地区、北美、欧洲、拉丁美洲和世界其他地区。由于慢性肾病患病率的增加以及该地区政府当局的积极举措，北美已成为市场份额方面的领先地区。另一方面，由于医疗费用增加以及高血压和糖尿病等生活方式相关疾病的流行，预计亚太地区在预测期内将出现显着增长。

本报告中的主要市场进入者包括：

  • Merck & Co.
  • F. Hoffman-La Roche Ltd.
  • Pfizer Inc.
  • Galectin Therapeutics
  • La Jolla Pharmaceutical Company
  • InterMune Inc.
  • ProMetic Life-Sciences Inc.
  • Genzyme Corporation
  • BioLine Rx Ltd
  • Certa Therapeutics

近期市场动态。

  • 2022 年 3 月，Zydus Lifesciences 获得了印度药品监管局（DCGI）批准的名为 Oxemia 的新药申请（NDA）。新药 Oxemia 是印度首个用于治疗与慢性肾病 (CKD) 相关的贫血的口服药物。
  • 2022年8月，Bayer在印度推出治疗2型糖尿病相关慢性肾病的新药Finelenone。这种新药将以 Kerendia 品牌在印度上市销售。
  • 2022 年 8 月，费城儿童医院 (CHOP) 和 Penn Medicine 宣布他们将联合启动 Penn-CHOP 肾臟创新中心。新中心将是世界上第一个推进肾臟疾病及其相关并发症的早期检测、预防和治疗研究的中心。

全球肾纤维化治疗市场研究范围。

历史数据： 2019-2020-2021

基准估计年份：2021

预测期：2022-2029

报告的收入预测、公司排名、竞争格局、增长因素、趋势

目标细分治疗剂、最终用户、地区

区域范围北美、欧洲、亚太地区、拉丁美洲、世界其他地区

购买调查覆盖率报告可免费获得定制（相当于最多 8 个分析师小时）。添加或更改国家、地区、航段范围*

这项研究的目的是定义近年来各个细分市场和国家的市场规模，并预测他们在未来几年的价值。该报告旨在捕捉被调查国家工业的定性和定量方面的情况。

它还提供了有关关键方面的详细信息，例如将定义市场未来增长的驱动因素和挑战。此外，它还包含供利益相关者投资的微观市场潜在机会，以及对主要参与者的竞争格局和产品供应的深入分析。市场的详细细分和子细分如下所述。

按药物

血管紧张素 II 受体阻滞剂 (ARB)

血管紧张素转换□ (ACE) 抑製剂

□非尼酮

肾素抑製剂

血管□□抑製剂

按最终用户

医院

诊所

家庭医疗

按地区

北美

美国

加拿大

欧洲

英国

德国

法国

西班牙

意大利

欧洲其他地区

亚太地区

中国

印度

日本

澳大利亚

韩国

其他亚太地区

拉丁美洲

巴西

墨西哥

世界其他地区

目录

第一章内容提要

  • 市场快照
  • 2019-2029 年按细分市场的全球市场估计和预测
    • 肾纤维化治疗市场：按地区划分，2019-2029
    • 肾纤维化治疗市场：按治疗药物分类，2019-2029
    • 肾纤维化治疗市场：按最终用户分类，2019-2029
  • 主要趋势
  • 调查方法
  • 调查先决条件

第二章肾纤维化治疗的全球市场定义和范围

  • 调查目的
  • 市场定义和范围
    • 调查范围
    • 产业进化
  • 调查目标年份
  • 货币兑换率

第三章全球肾纤维化治疗市场动态

  • 肾纤维化治疗市场影响分析（2019-2029）
    • 市场驱动力
      • 慢性肾脏病发病率增加
      • 对肾纤维化治疗的认识不断提高。
      • 主要市场参与者的战略举措。
    • 市场挑战
      • 复杂的监管审批流程
    • 市场机会
      • 政府当局的有利举措增加。
      • 生活方式相关疾病的传播

第四章全球肾纤维化治疗市场行业分析

  • 波特五力模型
    • 供应商的议价能力
    • 买方议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争对手之间的竞争
  • 波特五力模型的未来方法（2019-2029）
  • PEST分析
    • 政治的
    • 经济的
    • 社会的
    • 技术的
  • 招商引资模式
  • 分析师结论/建议
  • 顶级投资机会
  • 关键成功策略

第 5 章风险评估：COVID-19 的影响

  • 评估 COVID-19 对行业的整体影响
  • COVID-19 之前和 COVID-19 之后的市场情景

6 全球肾纤维化治疗市场，按治疗剂

  • 市场快照
  • 全球肾纤维化治疗市场：治疗学的性能潜力分析
  • 2019-2029 年全球肾纤维化治疗市场、治疗学估计和预测
  • 肾纤维化治疗市场，细分分析
    • 血管紧张素 II 受体阻滞剂 (ARB)
    • 血管紧张素转换□ (ACE) 抑製剂
    • □非尼酮
    • 肾素抑製剂
    • 血管□□抑製剂

7 全球肾纤维化治疗市场，按最终用户

  • 市场快照
  • 全球肾纤维化治疗市场：最终用户的性能潜力分析
  • 全球肾纤维化治疗市场、最终用户估计和预测（2019-2029）
  • 肾纤维化治疗市场，细分分析
    • 医院
    • 诊所
    • 家庭治疗

8 全球肾纤维化治疗市场：区域分析

  • 肾纤维化治疗市场的区域市场概况
  • 北美
    • 美国
      • 治疗药物的估计和预测，2019-2029
      • 最终用户的估计和预测，2019-2029
    • 加拿大
  • 欧洲肾纤维化治疗市场概况
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区肾纤维化治疗市场概况
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉丁美洲肾纤维化治疗市场概况
    • 巴西
    • 墨西哥
  • 世界其他地区

第 9 章 竞争信息

  • 顶级市场战略
  • 公司简介
    • Merck & Co.
      • 主要信息
      • 概述
      • 财务（取决于数据可用性）
      • 产品概要
      • 近期发展状况
    • F. Hoffman-La Roche Ltd.
    • Pfizer Inc
    • Galectin Therapeutics
    • La Jolla Pharmaceutical Company
    • InterMune Inc.
    • ProMetic Life-Sciences Inc.
    • Genzyme Corporation
    • BioLine Rx Ltd
    • Certa Therapeutics

第 10 章 调查过程

  • 调查过程
    • 数据挖掘
    • 分析
    • 市场估计
    • 验证
    • 出版物
  • 调查属性
  • 调查先决条件

Global Kidney Fibrosis Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Kidney Fibrosis refers to excessive production and deposition of extracellular matrix (ECM) proteins in the kidney interstitium. This excessive production and deposition of ECM causes structural damage, impairment of renal function, and leads to end-stage renal disease (ESRD). Diabetes and Hypertension are two leading causes of Kidney Fibrosis. Apart from these two as infectious glomerulonephritis, renal vasculitis, ureteral obstruction, genetic alterations, and autoimmune diseases among others also causes Kidney Fibrosis. The increasing incidence of chronic kidney diseases and rowing awareness towards renal fibrosis treatment as well as strategic initiatives from leading market player are key factors accelerating the market growth.

According to the Centers for Disease Control & Prevention - as of 2021, around 37 million US individual are affected by chronic kidney diseases, witnessing for over 15% of all US adults. Moreover, as per National Kidney Foundation estimates- in the United States more than 1 in 7 adults are diagnosed with chronic kidney disease. In addition, around 90% of individuals with kidney disease are not aware about their disease. Also, rising number of favorable initiatives from government authorities and increasing prevalence of lifestyle diseases would create lucrative growth prospectus for the market over the forecast period. However, complex process associated with regulatory approvals stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Kidney Fibrosis Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America the leading region in terms of market share owing to increasing prevalence of chronic kidney diseases as well as favorable initiatives from government authorities in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising healthcare spending as well as growing prevalence of lifestyle diseases such as hypertension and diabetes in the region.

Major market players included in this report are:

Merck & Co.

F. Hoffman-La Roche Ltd.

Pfizer Inc.

Galectin Therapeutics

La Jolla Pharmaceutical Company

InterMune Inc.

ProMetic Life-Sciences Inc.

Genzyme Corporation

BioLine Rx Ltd

Certa Therapeutics

Recent Developments in the Market:

  • In March 2022, Zydus Lifesciences received approval for its New Drug Application (NDA) named Oxemia from the Drug Controller General of India (DCGI). The new drug Oxemia, would be a first-of-its-kind oral treatment in India for anaemia associated with chronic kidney disease (CKD)
  • In August 2022, Bayer launched a new drug named finerenone for treatment of chronic kidney disease associated with type-2 diabetes in India. This new drug would be sold in India under brand name Kerendia.
  • In August 2022, USA based Children's Hospital of Philadelphia (CHOP) and Penn Medicine jointly announced the launch of Penn-CHOP Kidney Innovation Center. This new center would be first-of-its-kind and would work towards advance research for the early detection, prevention, and treatment of kidney disease and its associated complications.

Global Kidney Fibrosis Treatment Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered Therapeutics, End User, Region

Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Therapeutics

Angiotensin II receptor blockers (ARBs)

Angiotensin Converting Enzyme (ACE) inhibitors

Pirfenidone

Renin Inhibitors

Vasopeptidase Inhibitors

By End User

Hospital

Clinics

Home Treatment

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Kidney Fibrosis Treatment Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Kidney Fibrosis Treatment Market, by Therapeutics, 2019-2029 (USD Billion)
    • 1.2.3. Kidney Fibrosis Treatment Market, by End User, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Kidney Fibrosis Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Kidney Fibrosis Treatment Market Dynamics

  • 3.1. Kidney Fibrosis Treatment Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of chronic kidney diseases.
      • 3.1.1.2. Growing awareness towards renal fibrosis treatment.
      • 3.1.1.3. Strategic initiatives from leading market players.
    • 3.1.2. Market Challenges
      • 3.1.2.1. Complex regulatory approval procedures.
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing number of favourable initiatives from government authorities.
      • 3.1.3.2. Rising prevalence of lifestyle diseases.

Chapter 4. Global Kidney Fibrosis Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Kidney Fibrosis Treatment Market, by Therapeutics

  • 6.1. Market Snapshot
  • 6.2. Global Kidney Fibrosis Treatment Market by Therapeutics, Performance - Potential Analysis
  • 6.3. Global Kidney Fibrosis Treatment Market Estimates & Forecasts by Therapeutics 2019-2029 (USD Billion)
  • 6.4. Kidney Fibrosis Treatment Market, Sub Segment Analysis
    • 6.4.1. Angiotensin II receptor blockers (ARBs)
    • 6.4.2. Angiotensin Converting Enzyme (ACE) inhibitors
    • 6.4.3. Pirfenidone
    • 6.4.4. Renin Inhibitors
    • 6.4.5. Vasopeptidase Inhibitors

Chapter 7. Global Kidney Fibrosis Treatment Market, by End User

  • 7.1. Market Snapshot
  • 7.2. Global Kidney Fibrosis Treatment Market by End User, Performance - Potential Analysis
  • 7.3. Global Kidney Fibrosis Treatment Market Estimates & Forecasts by End User 2019-2029 (USD Billion)
  • 7.4. Kidney Fibrosis Treatment Market, Sub Segment Analysis
    • 7.4.1. Hospital
    • 7.4.2. Clinics
    • 7.4.3. Home Treatment

Chapter 8. Global Kidney Fibrosis Treatment Market, Regional Analysis

  • 8.1. Kidney Fibrosis Treatment Market, Regional Market Snapshot
  • 8.2. North America Kidney Fibrosis Treatment Market
    • 8.2.1. U.S. Kidney Fibrosis Treatment Market
      • 8.2.1.1. Therapeutics breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. End User breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Kidney Fibrosis Treatment Market
  • 8.3. Europe Kidney Fibrosis Treatment Market Snapshot
    • 8.3.1. U.K. Kidney Fibrosis Treatment Market
    • 8.3.2. Germany Kidney Fibrosis Treatment Market
    • 8.3.3. France Kidney Fibrosis Treatment Market
    • 8.3.4. Spain Kidney Fibrosis Treatment Market
    • 8.3.5. Italy Kidney Fibrosis Treatment Market
    • 8.3.6. Rest of Europe Kidney Fibrosis Treatment Market
  • 8.4. Asia-Pacific Kidney Fibrosis Treatment Market Snapshot
    • 8.4.1. China Kidney Fibrosis Treatment Market
    • 8.4.2. India Kidney Fibrosis Treatment Market
    • 8.4.3. Japan Kidney Fibrosis Treatment Market
    • 8.4.4. Australia Kidney Fibrosis Treatment Market
    • 8.4.5. South Korea Kidney Fibrosis Treatment Market
    • 8.4.6. Rest of Asia Pacific Kidney Fibrosis Treatment Market
  • 8.5. Latin America Kidney Fibrosis Treatment Market Snapshot
    • 8.5.1. Brazil Kidney Fibrosis Treatment Market
    • 8.5.2. Mexico Kidney Fibrosis Treatment Market
  • 8.6. Rest of The World Kidney Fibrosis Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Merck & Co.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. F. Hoffman-La Roche Ltd.
    • 9.2.3. Pfizer Inc
    • 9.2.4. Galectin Therapeutics
    • 9.2.5. La Jolla Pharmaceutical Company
    • 9.2.6. InterMune Inc.
    • 9.2.7. ProMetic Life-Sciences Inc.
    • 9.2.8. Genzyme Corporation
    • 9.2.9. BioLine Rx Ltd
    • 9.2.10. Certa Therapeutics

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Kidney Fibrosis Treatment Market, report scope
  • TABLE 2. Global Kidney Fibrosis Treatment Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Kidney Fibrosis Treatment Market estimates & forecasts by Therapeutics 2019-2029 (USD Billion)
  • TABLE 4. Global Kidney Fibrosis Treatment Market estimates & forecasts by End User 2019-2029 (USD Billion)
  • TABLE 5. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Kidney Fibrosis Treatment Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Kidney Fibrosis Treatment Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Kidney Fibrosis Treatment Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Kidney Fibrosis Treatment Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Kidney Fibrosis Treatment Market
  • TABLE 70. List of primary sources, used in the study of global Kidney Fibrosis Treatment Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Kidney Fibrosis Treatment Market, research methodology
  • FIG 2. Global Kidney Fibrosis Treatment Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Kidney Fibrosis Treatment Market, key trends 2021
  • FIG 5. Global Kidney Fibrosis Treatment Market, growth prospects 2022-2029
  • FIG 6. Global Kidney Fibrosis Treatment Market, porters 5 force model
  • FIG 7. Global Kidney Fibrosis Treatment Market, pest analysis
  • FIG 8. Global Kidney Fibrosis Treatment Market, value chain analysis
  • FIG 9. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Kidney Fibrosis Treatment Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Kidney Fibrosis Treatment Market, regional snapshot 2019 & 2029
  • FIG 15. North America Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Kidney Fibrosis Treatment Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Kidney Fibrosis Treatment Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable